Overview

A class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Company’s common stock traded on the NASDAQ Stock Market under the symbol “GERN.”

The Geron class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Geron securities between June 7, 2024, to February 25, 2025, both dates inclusive (the “Class Period”).

Geron is a commercial-stage biopharmaceutical company with a focus on blood cancer.  Geron’s primary product is a telomerase inhibitor, imetelstat, which the Company sells under the brand name, Rytelo.  It is designed to reduce the proliferation of malignant cells to permit the production of new healthy cells.

Rytelo was approved by the U.S. Food and Drug Administration (FDA) on June 6, 2024 for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks or who have not responded to or have lost response to or are otherwise ineligible for erythropoiesis-stimulating agents (“ESAs”).

The Geron class action lawsuit alleges that Defendants, throughout the Class Period, provided investors with material information concerning Defendants’ expectations for the launch and growth potential of Rytelo (imetelstat).  Defendants’ statements included, among other things, confidence in Geron’s ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug’s sales.

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Rytelo’s potential.

*          *          *

If you purchased or otherwise acquired Geron securities between June 7, 2024, and February 25, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Geron class action lawsuit is May 12, 2025.